|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis显示文摘 | Kalaitzakis E Sadik R Holst J J | | 0，，03： | 1 |
| 2 | Etiology of portal hapertension may in fluence gastrion test in altransit 显示文摘 | SADIK R ABAHAMSSON H BJORNSSON E | 2003 | Scand J Gastroenterol2003，38，： | 1 |
| 3 | Gender differences in gut transit shown with anewly developed radiological procedure显示文摘 | Sadik R Abrahamsson H Stotxer PO | 2003 | Scand J Gastroenterol2003，38，1： | 1 |
| 4 | Etiology of portal hypertension may influence gastrointestinal transit 显示文摘 | Sadik R Abrahamsson H Bjornsson E | 2003 | Scand J Gastroenterol2003，38，10： | 1 |
| 5 | Etiology of portal hypertension may influence gastrointestinal transit显示文摘 | Sadik R Abrahamsson H Bjornsson E | 2003 | Scand J Gastroenterol2003，38，10： | 1 |
| 6 | Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension 显示文摘 | Gunnarsdottir S A Sadik R Shev S | 2003 | Am J Gastroenterol2003，98，6： | 1 |
| 7 | Small intestinal motility disturbances and bacterial o- vergrowth in patients with liver cirrhosis and portal hypertension显示文摘 | GUNNARSDOTTIR S A SADIK R SHEV S | 2003 | Am J Gastroenterol2003，98，： | 1 |
| 8 | Etiology of portal hypertension may influence gastrointestinal transit 显示文摘 | Sadik R Abrahamsson H Bjornsson E | 2003 | Scand J Gastroenterol2003，38，10： | 1 |
| 9 | The relationship between symp-toms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome显示文摘 | Sadik R Bjornsson E Simren M | 2010 | EurJ Gastroenterol Hepa-tol2010，22，： | 1 |
| 10 | Colonic transit time and IBS symptoms: what' s the link?显示文摘 | Tornblom H Van Oudenhove L Sadik R | 2012 | AmJ Gastroenterol2012，107，5： | 1 |
| 11 | Antimicrobial and cytotoxic constituents of Loranthus globosus 显示文摘 | Sadik G Islam R Rahman M M | 2003 | Fitoterapia2003，74，3： | 1 |
| 12 | Gender differences in gut transit shown with a newly developed radiological procedure显示文摘 | Sadik R Abrahamsson H Stotzer PO | 2003 | Scand J Gastroenterol2003，38，1： | 1 |
| 13 | Etiology of portal hapertension may influence gastrion test inaltransit 显示文摘 | SADIK R ABAHAMSSON H BJORNSSON E | 2003 | Scand Gastroenterol2003，38，： | 1 |
| 14 | Effects on gastroin- testinal transit and antroduodenojejunal manometry after gut-directed hypnotherapy in irritable bowel syndrome (IBS)显示文摘 | Lindfors P Tornblom H Sadik R | 2012 | Scand J Gastroenterol2012，47，12： | 1 |
| 15 | Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension 显示文摘 | GUNNARSDOTTIR SA SADIK R SHEV S | 2003 | Am J Gastroenterol2003，98，6： | 1 |
| 16 | Etiology of portal yhertension may influence gastrointestinal transit显示文摘 | Sadik R Abrahmsson H Bjornsson E | 2003 | Scand J Gastroenterol2003，38，10： | 1 |
| 17 | Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension显示文摘 | Gunnarsdottir S A Sadik R Shev S | 2003 | Am J Gastro enterol2003，98，6： | 1 |
| 18 | Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension显示文摘 | Gunnarsdottir SA Sadik R Shev S | 2003 | Am J Gastroenterol2003，98，13： | 1 |
| 19 | Comparison of two different treatment regimens’ efficacy in neovascular age-related macular degeneration in Turkish population—based on real life data-Bosphorus RWE Study Group显示文摘AIM: To compare two different anti-vascular endothelial growth factor(anti-VEGF) treatment regimens'-a priori pro re nata(PRN) and PRN regimen following^(th)e loading phaseanatomical and functional results in neovascular agerelated macular degeneration(n AMD) patients. METHODS: Totally 544 n AMD patients followed and treated with aflibercept(n=135) and ranibizumab(n=409)at 9 different centers between 2013 and 2015 were enrolled into^(th)is retrospective multicenter study. Patients with initial best corrected visual acuity(BCVA) interval of 1.3-0.3(log MAR) and a minimum follow-up of 12 mo were included. Patients under two different regimens-a priori pro re nata(1+PRN) or 3 consecutive intravitreal injections followed by a PRN regimen(3+PRN)-were compared in BCVA at 3^(th), 6^(th) and 12^(th) months, and in central macular^(th)ickness(CMT) at 6^(th) and 12^(th) months. The total study group, intravitreal ranibizumab(IVR) and intravitreal aflibercept(IVA) groups were evaluated separately. RESULTS: The mean CMT decreased in^(th)e 1+PRN(n=101) regimen from 407 to 358 and 340 μm and in^(th)e 3+PRN(n=443) group from 398 to 318 and finally to 310 μm at months 6 and 12, respectively. Anatomically,^(th)e CMT reduction at 6^(th) month(48.5 vs 76.4;P<0.05) was statistically significant in favor of 3+PRN group. BCVA changed in 1+PRN group from 0.77 to 0.78, 0.75 and 0.75;in 3+PRN group from 0.81 to 0.69, 0.72, and 0.76 at months 3, 6, and 12, respectively. Visual gain was statistically better in 3+PRN group at 3^(th) month(-0.01 vs 0.12;P<0.001). In IVR group, CMT reduction was in greater in 3+PRN at 6^(th)(44 vs 72) and 12^(th) month(61 vs 84), but statistically insignificant. The 3+PRN group revealed statistically better visual results at 3^(th) month(-0.02 vs 0.11, P<0.05). In IVA group, although statistically insignificant, CMT reduction(61 vs 89, 6^(th) month;85 vs 97, 12^(th) month) and visual gain(0.02 vs 0.16;0.02 vs 0.14;0.05 vs 0.11) was found in favor of 3+PRN group at all visits.CONCLUSION: The loading dose of anti-VEGF treatments in n AMD leads to significantly better anatomical and functional results, regardless of the agent, specially in early follow-up interval. | Burak Erden Selim Bolükbasi Abdullah Ozkaya Levent Karabas Cengiz Alagoz Zeynep Alkin Ozgür Artunay Sadik Etka Bayramoglu Gokhan Demir Mehmet Demir Ali Demircan Gürkan Erdogan Mehmet Erdogan Erdem Eris Havva Kaldirim Ismail Umut Onur Ozen Ayranci Osmanbasoglu Sezin Ozdogan Erkul Mine Oztürk Irfan Perente Kübra Sarici Nihat Sayin Dilek Yasa Ihsan Yilmaz Zeynep Yilmazabdurrahmanoglu 无 | 2020 | International Journal of Ophthalmology(English edition)2020，13，1： | 1 |
| 20 | Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis显示文摘 | Kalaitzakis E Sadik R Holst JJ | 2009 | Clin Gastroenterol Hepatol2009，7，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员